Global X Japan Co. Ltd. Has $6.80 Million Position in Amgen Inc. $AMGN

Global X Japan Co. Ltd. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 342.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,787 shares of the medical research company’s stock after purchasing an additional 16,094 shares during the quarter. Global X Japan Co. Ltd.’s holdings in Amgen were worth $6,804,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. West Family Investments Inc. grew its holdings in Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after buying an additional 30 shares in the last quarter. Viawealth LLC increased its stake in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after acquiring an additional 30 shares during the period. LOM Asset Management Ltd grew its holdings in shares of Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock worth $721,000 after purchasing an additional 30 shares in the last quarter. Sittner & Nelson LLC grew its stake in Amgen by 0.4% during the third quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock worth $2,053,000 after buying an additional 30 shares in the last quarter. Finally, TAGStone Capital Inc. lifted its holdings in shares of Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after acquiring an additional 32 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.2%

Shares of Amgen stock opened at $353.16 on Friday. The stock’s 50-day moving average is $362.22 and its 200 day moving average is $329.40. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The firm has a market cap of $190.38 billion, a price-to-earnings ratio of 24.82, a PEG ratio of 3.51 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Rothschild & Co Redburn lifted their price target on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. HSBC reiterated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research report on Wednesday, December 10th. Guggenheim upped their price objective on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Royal Bank Of Canada lifted their target price on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Finally, Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a research report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.